Details of the Drug

General Information of Drug (ID: DMGB035)

Drug Name

Armodafinil

Synonyms

Nuvigil; 112111-43-0; (R)-Modafinil; (R)-(-)-Modafinil; CEP-10953; UNII-V63XWA605I; CRL 40982; CEP 10953; V63XWA605I; CHEMBL1201192; CHEBI:77590; 2-[(R)-(Diphenylmethyl)sulfinyl]acetamide; (-)-2-((R)-(Diphenylmethyl)sulfinyl)acetamide; (-)-2-[(r)-(diphenylmethyl)sulfinyl]acetamide; Armodafinil [USAN:INN]; armodafinilo; armodafinilum; l-Modafinil; Nuvigil (TN); (-)-(R)-modafinil; Armodafinil (USAN/INN); SCHEMBL34489; ZINC6156; ACE037; Armodafinil, > YFGHCGITMMYXAQ-LJQANCHMSA-N

Indication

Disease Entry	ICD 11	Status	REF
Malignant glioma	2A00.0	Approved	[1]
Methamphetamine dependence	6C46.2	Approved	[1]
Narcolepsy	7A20	Approved	[1]
Pain	MG30-MG3Z	Approved	[1]
Pediatric cancer	2A00-2F9Z	Approved	[2]
Postpoliomyelitis syndrome	N.A.	Approved	[1]
Traumatic brain injury	NA07.Z	Approved	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of Indication(s)

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

273.4

Logarithm of the Partition Coefficient (xlogp)

1.7

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
Clearance: The apparent oral clearance of drug is 33 mL/min []
Elimination: 8% of drug is excreted from urine in the unchanged form [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 15 hours [4]
Metabolism: The drug is metabolized via the cytochrome P450 (CYP) 3A4/5 []
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 13.0649 micromolar/kg/day [5]
Vd: The volume of distribution (Vd) of drug is 42 L []

Chemical Identifiers

Formula: C15H15NO2S
IUPAC Name: 2-[(R)-benzhydrylsulfinyl]acetamide
Canonical SMILES: C1=CC=C(C=C1)C(C2=CC=CC=C2)[S@](=O)CC(=O)N
InChI: InChI=1S/C15H15NO2S/c16-14(17)11-19(18)15(12-7-3-1-4-8-12)13-9-5-2-6-10-13/h1-10,15H,11H2,(H2,16,17)/t19-/m1/s1
InChIKey: YFGHCGITMMYXAQ-LJQANCHMSA-N

Cross-matching ID

PubChem CID: 9690109
ChEBI ID: CHEBI:77590
CAS Number: 112111-43-0
DrugBank ID: DB06413
TTD ID: D0J5RN
VARIDT ID: DR00998
INTEDE ID: DR0137
ACDINA ID: D00044

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adrenergic receptor alpha-1D (ADRA1D)	TT34BHT	ADA1D_HUMAN	Agonist	[6]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[7]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Substrate	[8]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Armodafinil

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Larotrectinib	DM26CQR	Moderate	Increased metabolism of Armodafinil caused by Larotrectinib mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[9]
LEE011	DMMX75K	Moderate	Increased metabolism of Armodafinil caused by LEE011 mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[9]
-----------

Coadministration of a Drug Treating the Disease Different from Armodafinil (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Ivosidenib	DM8S6T7	Moderate	Increased metabolism of Armodafinil caused by Ivosidenib mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[10]
Midostaurin	DMI6E0R	Moderate	Increased metabolism of Armodafinil caused by Midostaurin mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[11]
Gilteritinib	DMTI0ZO	Moderate	Increased metabolism of Armodafinil caused by Gilteritinib mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[12]
Oliceridine	DM6MDCF	Major	Increased metabolism of Armodafinil caused by Oliceridine mediated induction of CYP450 enzyme.	Acute pain [MG31]	[13]
Ivabradine	DM0L594	Moderate	Increased metabolism of Armodafinil caused by Ivabradine mediated induction of CYP450 enzyme.	Angina pectoris [BA40]	[14]
Bedaquiline	DM3906J	Minor	Increased metabolism of Armodafinil caused by Bedaquiline mediated induction of CYP450 enzyme.	Antimicrobial drug resistance [MG50-MG52]	[15]
Troleandomycin	DMUZNIG	Minor	Decreased metabolism of Armodafinil caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[9]
Erdafitinib	DMI782S	Moderate	Decreased clearance of Armodafinil due to the transporter inhibition by Erdafitinib.	Bladder cancer [2C94]	[16]
Pexidartinib	DMS2J0Z	Moderate	Increased metabolism of Armodafinil caused by Pexidartinib mediated induction of CYP450 enzyme.	Bone/articular cartilage neoplasm [2F7B]	[17]
HKI-272	DM6QOVN	Minor	Increased metabolism of Armodafinil caused by HKI-272 mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[15]
LY2835219	DM93VBZ	Moderate	Increased metabolism of Armodafinil caused by LY2835219 mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[18]
Esterified estrogens	DM9KZDO	Minor	Increased metabolism of Armodafinil caused by Esterified estrogens mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[15]
Tucatinib	DMBESUA	Minor	Decreased metabolism of Armodafinil caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[9]
Palbociclib	DMD7L94	Moderate	Increased metabolism of Armodafinil caused by Palbociclib mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[9]
Alpelisib	DMEXMYK	Moderate	Increased metabolism of Armodafinil caused by Alpelisib mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[19]
Cabazitaxel	DMPAZHC	Minor	Increased metabolism of Armodafinil caused by Cabazitaxel mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[15]
Bosutinib	DMTI8YE	Moderate	Increased metabolism of Armodafinil caused by Bosutinib mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[20]
Macitentan	DMP79A1	Minor	Increased metabolism of Armodafinil caused by Macitentan mediated induction of CYP450 enzyme.	Cardiovascular disease [BA00-BE2Z]	[15]
PF-04449913	DMSB068	Moderate	Increased metabolism of Armodafinil caused by PF-04449913 mediated induction of CYP450 enzyme.	Chronic myelomonocytic leukaemia [2A40]	[21]
Levonorgestrel	DM1DP7T	Moderate	Increased metabolism of Armodafinil caused by Levonorgestrel mediated induction of CYP450 enzyme.	Contraceptive management [QA21]	[9]
Ulipristal	DMBNI20	Moderate	Increased metabolism of Armodafinil caused by Ulipristal mediated induction of CYP450 enzyme.	Contraceptive management [QA21]	[14]
Osilodrostat	DMIJC9X	Moderate	Increased metabolism of Armodafinil caused by Osilodrostat mediated induction of CYP450 enzyme.	Cushing syndrome [5A70]	[22]
Lumacaftor	DMCLWDJ	Moderate	Increased metabolism of Armodafinil caused by Lumacaftor mediated induction of CYP450 enzyme.	Cystic fibrosis [CA25]	[10]
Ivacaftor	DMZC1HS	Minor	Decreased metabolism of Armodafinil caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[9]
MK-8228	DMOB58Q	Minor	Decreased metabolism of Armodafinil caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[9]
Vilazodone	DM4LECQ	Minor	Increased metabolism of Armodafinil caused by Vilazodone mediated induction of CYP450 enzyme.	Depression [6A70-6A7Z]	[15]
OPC-34712	DMHG57U	Minor	Increased metabolism of Armodafinil caused by OPC-34712 mediated induction of CYP450 enzyme.	Depression [6A70-6A7Z]	[15]
Esketamine	DMVU687	Major	Additive hypertensive effects by the combination of Armodafinil and Esketamine.	Depression [6A70-6A7Z]	[9]
Oestradiol valerate and dienogest	DMZK0FQ	Moderate	Increased metabolism of Armodafinil caused by Oestradiol valerate and dienogest mediated induction of CYP450 enzyme.	Endometriosis [GA10]	[23]
Stiripentol	DMMSDOY	Moderate	Increased metabolism of Armodafinil caused by Stiripentol mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[14]
Eslicarbazepine	DMZREFQ	Moderate	Increased metabolism of Armodafinil caused by Eslicarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[10]
Bay 80-6946	DMLOS5R	Moderate	Increased metabolism of Armodafinil caused by Bay 80-6946 mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[24]
Tazemetostat	DMWP1BH	Moderate	Increased metabolism of Armodafinil caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[25]
Mirabegron	DMS1GYT	Minor	Increased metabolism of Armodafinil caused by Mirabegron mediated induction of CYP450 enzyme.	Functional bladder disorder [GC50]	[26]
Ripretinib	DM958QB	Moderate	Increased metabolism of Armodafinil caused by Ripretinib mediated induction of CYP450 enzyme.	Gastrointestinal stromal tumour [2B5B]	[9]
Avapritinib	DMK2GZX	Moderate	Increased metabolism of Armodafinil caused by Avapritinib mediated induction of CYP450 enzyme.	Gastrointestinal stromal tumour [2B5B]	[14]
Boceprevir	DMBSHMF	Minor	Decreased metabolism of Armodafinil caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[9]
GS-5885	DMSL3DX	Moderate	Decreased clearance of Armodafinil due to the transporter inhibition by GS-5885.	Hepatitis virus infection [1E50-1E51]	[27]
MK-1439	DM215WE	Moderate	Increased metabolism of Armodafinil caused by MK-1439 mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[28]
Fostemsavir	DM50ILT	Minor	Increased metabolism of Armodafinil caused by Fostemsavir mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[29]
Cobicistat	DM6L4H2	Moderate	Increased metabolism of Armodafinil caused by Cobicistat mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[13]
Dolutegravir	DMCZGRE	Minor	Increased metabolism of Armodafinil caused by Dolutegravir mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[15]
Etravirine	DMGV8QU	Moderate	Increased metabolism of Armodafinil caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[30]
Rilpivirine	DMJ0QOW	Moderate	Increased metabolism of Armodafinil caused by Rilpivirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[9]
BMS-201038	DMQTAGO	Moderate	Decreased clearance of Armodafinil due to the transporter inhibition by BMS-201038.	Hyper-lipoproteinaemia [5C80]	[31]
Levamlodipine	DM92S6N	Minor	Increased metabolism of Armodafinil caused by Levamlodipine mediated induction of CYP450 enzyme.	Hypertension [BA00-BA04]	[15]
Lesinurad	DMUR64T	Moderate	Increased metabolism of Armodafinil caused by Lesinurad mediated induction of CYP450 enzyme.	Inborn purine/pyrimidine/nucleotide metabolism error [5C55]	[10]
Suvorexant	DM0E6S3	Minor	Decreased metabolism of Armodafinil caused by Suvorexant mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[9]
Tasimelteon	DMLOQ1V	Moderate	Increased metabolism of Armodafinil caused by Tasimelteon mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[32]
Naloxegol	DML0B41	Minor	Increased metabolism of Armodafinil caused by Naloxegol mediated induction of CYP450 enzyme.	Large intestine motility disorder [DB32]	[15]
Pemigatinib	DM819JF	Moderate	Increased metabolism of Armodafinil caused by Pemigatinib mediated induction of CYP450 enzyme.	Liver cancer [2C12]	[14]
Crizotinib	DM4F29C	Minor	Decreased metabolism of Armodafinil caused by Crizotinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[9]
Brigatinib	DM7W94S	Moderate	Increased metabolism of Armodafinil caused by Brigatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[9]
Ceritinib	DMB920Z	Moderate	Increased metabolism of Armodafinil caused by Ceritinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[33]
Lurbinectedin	DMEFRTZ	Moderate	Increased metabolism of Armodafinil caused by Lurbinectedin mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[34]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Armodafinil caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[10]
Osimertinib	DMRJLAT	Moderate	Increased metabolism of Armodafinil caused by Osimertinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[35]
Capmatinib	DMYCXKL	Moderate	Decreased clearance of Armodafinil due to the transporter inhibition by Capmatinib.	Lung cancer [2C25]	[36]
Selpercatinib	DMZR15V	Moderate	Increased metabolism of Armodafinil caused by Selpercatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[14]
Artemether	DM48QOT	Moderate	Increased metabolism of Armodafinil caused by Artemether mediated induction of CYP450 enzyme.	Malaria [1F40-1F45]	[9]
Idelalisib	DM602WT	Minor	Decreased metabolism of Armodafinil caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[9]
GDC-0199	DMH0QKA	Moderate	Increased metabolism of Armodafinil caused by GDC-0199 mediated induction of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[37]
IPI-145	DMWA24P	Moderate	Increased metabolism of Armodafinil caused by IPI-145 mediated induction of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[38]
Acalabrutinib	DM7GCVW	Moderate	Increased metabolism of Armodafinil caused by Acalabrutinib mediated induction of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[39]
Ibrutinib	DMHZCPO	Minor	Increased metabolism of Armodafinil caused by Ibrutinib mediated induction of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[15]
Ponatinib	DMYGJQO	Minor	Increased metabolism of Armodafinil caused by Ponatinib mediated induction of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[15]
Vemurafenib	DM62UG5	Moderate	Increased metabolism of Armodafinil caused by Vemurafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[40]
Selumetinib	DMC7W6R	Moderate	Increased metabolism of Armodafinil caused by Selumetinib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[41]
LGX818	DMNQXV8	Moderate	Increased metabolism of Armodafinil caused by LGX818 mediated induction of CYP450 enzyme.	Melanoma [2C30]	[42]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Armodafinil caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[14]
Ubrogepant	DM749I3	Moderate	Increased metabolism of Armodafinil caused by Ubrogepant mediated induction of CYP450 enzyme.	Migraine [8A80]	[43]
Lasmiditan	DMXLVDT	Moderate	Decreased clearance of Armodafinil due to the transporter inhibition by Lasmiditan.	Migraine [8A80]	[44]
Panobinostat	DM58WKG	Moderate	Increased metabolism of Armodafinil caused by Panobinostat mediated induction of CYP450 enzyme.	Multiple myeloma [2A83]	[45]
Ruxolitinib	DM7Q98D	Minor	Increased metabolism of Armodafinil caused by Ruxolitinib mediated induction of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[15]
Rolapitant	DM8XP26	Moderate	Increased metabolism of Armodafinil caused by Rolapitant mediated induction of CYP450 enzyme.	Nausea/vomiting [MD90]	[46]
Netupitant	DMEKAYI	Minor	Decreased metabolism of Armodafinil caused by Netupitant mediated inhibition of CYP450 enzyme.	Nausea/vomiting [MD90]	[9]
Entrectinib	DMMPTLH	Moderate	Increased metabolism of Armodafinil caused by Entrectinib mediated induction of CYP450 enzyme.	Non-small cell lung cancer [2C25]	[47]
S-297995	DM26IH8	Minor	Increased metabolism of Armodafinil caused by S-297995 mediated induction of CYP450 enzyme.	Opioid use disorder [6C43]	[15]
Olaparib	DM8QB1D	Major	Increased metabolism of Armodafinil caused by Olaparib mediated induction of CYP450 enzyme.	Ovarian cancer [2C73]	[9]
Rucaparib	DM9PVX8	Minor	Decreased metabolism of Armodafinil caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[9]
Istradefylline	DM20VSK	Minor	Increased metabolism of Armodafinil caused by Istradefylline mediated induction of CYP450 enzyme.	Parkinsonism [8A00]	[15]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Armodafinil caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[48]
Macimorelin	DMQYJIR	Moderate	Increased metabolism of Armodafinil caused by Macimorelin mediated induction of CYP450 enzyme.	Pituitary gland disorder [5A60-5A61]	[49]
Lefamulin	DME6G97	Moderate	Increased metabolism of Armodafinil caused by Lefamulin mediated induction of CYP450 enzyme.	Pneumonia [CA40]	[50]
Lonafarnib	DMGM2Z6	Moderate	Increased metabolism of Armodafinil caused by Lonafarnib mediated induction of CYP450 enzyme.	Premature ageing appearance [LD2B]	[51]
Enzalutamide	DMGL19D	Moderate	Increased metabolism of Armodafinil caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[52]
Darolutamide	DMV7YFT	Moderate	Increased metabolism of Armodafinil caused by Darolutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[53]
Riociguat	DMXBLMP	Minor	Increased metabolism of Armodafinil caused by Riociguat mediated induction of CYP450 enzyme.	Pulmonary hypertension [BB01]	[15]
Axitinib	DMGVH6N	Moderate	Increased metabolism of Armodafinil caused by Axitinib mediated induction of CYP450 enzyme.	Renal cell carcinoma [2C90]	[54]
Upadacitinib	DM32B5U	Minor	Increased metabolism of Armodafinil caused by Upadacitinib mediated induction of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[15]
Tofacitinib	DMBS370	Minor	Increased metabolism of Armodafinil caused by Tofacitinib mediated induction of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[15]
LDE225	DMM9F25	Moderate	Increased metabolism of Armodafinil caused by LDE225 mediated induction of CYP450 enzyme.	Skin cancer [2C30-2C37]	[55]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Armodafinil caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[14]
Fostamatinib	DM6AUHV	Moderate	Increased metabolism of Armodafinil caused by Fostamatinib mediated induction of CYP450 enzyme.	Thrombocytopenia [3B64]	[56]
Apixaban	DM89JLN	Minor	Increased metabolism of Armodafinil caused by Apixaban mediated induction of CYP450 enzyme.	Thrombosis [DB61-GB90]	[15]
Brilinta	DMBR01X	Moderate	Increased metabolism of Armodafinil caused by Brilinta mediated induction of CYP450 enzyme.	Thrombosis [DB61-GB90]	[13]
Cabozantinib	DMIYDT4	Moderate	Increased metabolism of Armodafinil caused by Cabozantinib mediated induction of CYP450 enzyme.	Thyroid cancer [2D10]	[57]
Linagliptin	DMWFJTR	Moderate	Increased metabolism of Armodafinil caused by Linagliptin mediated induction of CYP450 enzyme.	Type 2 diabetes mellitus [5A11]	[58]
Elagolix	DMB2C0E	Moderate	Increased metabolism of Armodafinil caused by Elagolix mediated induction of CYP450 enzyme.	Uterine fibroid [2E86]	[59]
-----------


⏷ Show the Full List of 99 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Sodium stearyl fumarate	E00545	23665634	lubricant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Carmellose sodium	E00625	Not Available	Disintegrant
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Vinylpyrrolidone	E00668	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
--------------------


⏷ Show the Full List of 8 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Armodafinil 100 mg tablet	100 mg	Oral Tablet	Oral
Armodafinil 150 mg tablet	150 mg	Oral Tablet	Oral
Armodafinil 200 mg tablet	200 mg	Oral Tablet	Oral
Armodafinil 250 mg tablet	250 mg	Oral Tablet	Oral
Armodafinil 50 mg tablet	50 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Armodafinil FDA Label
2	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3	BDDCS applied to over 900 drugs
4	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6	Mechanisms of modafinil: A review of current research. Neuropsychiatr Dis Treat. 2007 June; 3(3): 349-364.
7	Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects. Clin Pharmacokinet. 2008;47(1):61-74.
8	Clinical pharmacokinetic profile of modafinil. Clin Pharmacokinet. 2003;42(2):123-37.
9	Cerner Multum, Inc. "Australian Product Information.".
10	Product Information. Nuvigil (armodafinil). Cephalon Inc, West Chester, PA.
11	Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261]
12	Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
13	Canadian Pharmacists Association.
14	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
15	Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
16	Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
17	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
18	Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
19	Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
20	Product Information. Bosulif (bosutinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
21	Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
22	Product Information. Isturisa (osilodrostat). Recordati Rare Diseases Inc, Lebanon, NJ.
23	Faculty of Sexual & Reproductive Healthcare "FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception.".
24	Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT.
25	Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
26	Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
27	Product Information. Harvoni (ledipasvir-sofosbuvir). Gilead Sciences, Foster City, CA.
28	Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
29	Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
30	Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
31	Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
32	Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
33	Product Information. Zykadia (ceritinib). Novartis Pharmaceuticals, East Hanover, NJ.
34	Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
35	Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
36	Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
37	Product Information. Venclexta (venetoclax). AbbVie US LLC, North Chicago, IL.
38	Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
39	Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
40	Product Information. Zelboraf (vemurafenib). Genentech, South San Francisco, CA.
41	Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
42	Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
43	Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
44	Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
45	Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
46	Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
47	Product Information. Rozlytrek (entrectinib). Genentech, South San Francisco, CA.
48	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
49	Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
50	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
51	Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
52	Product Information. Xtandi (enzalutamide). Astellas Pharma US, Inc, Deerfield, IL.
53	Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
54	Pithavala YK, Tortorici M, Toh M, et al "Effect of rifampin on the pharmacokinetics of axitinib (AG-013736) in Japanese and Caucasian healthy volunteers." Cancer Chemother Pharmacol 65 (2010): 563-70. [PMID: 19603168]
55	Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
56	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
57	Product Information. Cabometyx (cabozantinib). Exelixis Inc, S San Francisco, CA.
58	Product Information. Tradjenta (linagliptin). Boehringer Ingelheim, Ridgefield, CT.
59	Product Information. Orilissa (elagolix). AbbVie US LLC, North Chicago, IL.